Cell Guidance Systems Launches £250k Funding Round on SyndicateRoom
News Oct 16, 2015
SyndicateRoom has launched a £250,000 funding round for Cell Guidance Systems, the revolutionary regenerative medicine company focused on the development of new technologies to enable dramatic advances in medical care.
Cell Guidance Systems has developed a range of successful products used by medical researchers to study, maintain and direct the behaviour of cells and cell secretions. It has a loyal customer base, including pharmaceutical companies such as Astra Zeneca, as well as almost all major UK universities and many in Europe and the US.
Revenues have increased by 40% to date in 2015, and now the company is seeking investment to scale up manufacturing, accelerate R&D and hire new scientists. It is also looking to play a more direct role in the development of regenerative medicines by continuing to develop its revolutionary Pods™ (polyhedral delivery system) technology, which has the potential to transform medical care for a range of untreatable diseases with an urgent unmet medical need.
Pods™ enables growth factors, the chemicals currently in use to artificially stimulate cell growth, to persist in the body for months, transforming their therapeutic efficacy. In their current form, growth factors are unstable and stop working after minutes or hours making them unsuitable for use outside of lab experiments.
The clinical potential of this technology is significant, offering real hope for individuals suffering from a myriad of conditions, including neurodegenerative diseases, such as Parkinson’s and motor neuron disease, as well as stroke, cardiac diseases, organ failure and spinal injury. The technology also has potential for the delivery of oral vaccines. Pods™ is covered by a set of four granted patents to which Cell Guidance Systems has exclusive, global rights in all fields, including therapeutics.
Cell Guidance Systems is seeking further investment primarily to accelerate its research in this exciting area. It is looking to increase the numbers of growth factors that are available, scale up production and, alongside collaborators, test the growth factors in models of disease to demonstrate pre-clinical proof of concept.
The lead investor on the funding round is Dr Steve Chambers, a founding partner of Adgen Ltd, a company which was sold to Nasdaq listed Neogen Corporation. Steve has remained with Adgen for the past 12 years, and is an angel investor focused on life sciences and biotechnology.
Michael Jones PhD, CEO of Cell Guidance Systems, said: “This funding round will enable us to further develop our unique ground breaking technologies which will have a dramatic impact on the field of regenerative medicine. Syndicate Room’s investor-led approach is perfect for this stage of our fundraising and gives us access to a significant pool of capital.”
Goncalo de Vasconcelos, CEO of SyndicateRoom, said: “This is an exciting opportunity for investors to access the high growth market of regenerative medicine, backing an already profitable company with a top quality management team. Cell Guidance Systems’ products are genuinely revolutionary and we look forward to working with them to complete their fundraise.”
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.